Fc-13 GalR2 might represent a new frontier being utilized to develop tailored smart therapeutics for neuropathic pain.
Neurolieve Biosciences is striving to provide with a groundbreaking, bioengineered protein-based therapy (Fc-13 GalR2) showing an accumulation on DRG (Dorsal Root Ganglia) and lack of CNS blood brain barrier penetrance. Fc-13 GalR2 might represent a new frontier being utilized to develop tailored smart therapeutics for peripheral neuropathy. This novel solution directly interacts with nerve cell mechanisms to decrease pain sensitivity and is designed to target the pain at its source. It offers the potential for substantial pain relief without the common side effects, representing a significant leap forward in neuropathic pain management